Recent Accomplishments by Juvaris BioTherapeutics:

 Advanced corporate partnering discussions
 Completed $12 million series A financing
 Several issued and pending NIH grants
 Initiated multiple collaborations                 

                                                                                                         
News Archive

05.28.08
Juvaris BioTherapeutics Initiates Phase I Clinical Trial of JVRS-100 Adjuvanted Seasonal Influenza Vaccine

03.13.08
Juvaris BioTherapeutics Announces the Appointment of Grant E. Pickering as Chief Executive Officer

03.04.08
Bayer HealthCare and Juvaris BioTherapeutics announce major licensing agreement

01.22.08
Carol L. Brosgart, M.D., Appointed to the Board of Directors of Juvaris BioTherapeutics, Inc.

01.15.08
Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement with the Centers for Disease Control and Prevention

09.26.07
Juvaris BioTherapeutics Announces Six Scientific Presentations at the Infectious Diseases Society of America (IDSA) meeting.

07.31.07
Juvaris BioTherapeutics Announces Award of U01 Cooperative Research Partnership from NIAID

06.06.07
Lewis T. "Rusty" Williams, M.D., Ph.D. Appointed to the Board of Directors of Juvaris BioTherapeutics, Inc.

02.07.07
Juvaris BioTherapeutics to Present at the 9th Annual BIO CEO & Investor Conference

01.08.07
Juvaris BioTherapeutics Announces First Round Closing of Series A Financing

09.26.06
Juvaris BioTherapeutics Announces Award Award of SBIR Grant for Acute Myelogenous Leukemia Vaccine Development

09.13.06
Juvaris BioTherapeutics Announces Award of Small Business Innovation Research (SBIR) Grant for Pathogen Countermeasures Development

03.07.06
Juvaris BioTherapeutics Announces Recieving NIH Grant Award for HIV Vaccine Development

03.01.06
Juvaris BioTherapeutics Announces Publication of JuvImmne Antiviral Efficacy for Punta Toro Virus Infection in a Prophylactic and a Therapeutic Rodent Model

01.09.06
Juvaris BioTherapeutics Receives NIH Grant for Development of Influenza A Virus Vaccine

11.02.05
Juvaris BioTherapeutics to Present at Rodman and RenshawTechvest 7th Annual Healthcare Conference

04.12.05
Juvaris BioTherapeutics Effectiveness of the JuvImmune Immunostimulant for AntiViral Applications

03.23.05
Juvaris BioTherapeutics Announces Collaboration with the International AIDS Vaccine Initiative

10.13.04
Juvaris BioTherapeutics Announces Evaluation of Products for Antiviral Application

10.05.04
Juvaris BioTherapeutics Announces Evaluation of Products for Biodefense Applications

09.28.04
Juvaris BioTherapeutics Announces Collaboration with Penn State Univeristy for Acute Myelogenous Leukemia

06.04.04
Juvaris BioTherapeutics Expands Relationship With Valentis

05.25.04
Juvaris Announces Licensing Agreement for New Therapeutic Vaccine Platform

05.18.04
Juvaris Announces Phase I SBIR for the Development of Pseudomonas Aeruginosa Vaccine

05.12.04
Juvaris and SomaGenics Announce Collaboration on Combination Products

01.08.04
Juvaris Announces Broad Patent Coverage for it's Core Technology Platform

09.17.03
Eugene"Gene" Mancino Appointed to the Board of Directors of Juvaris BioTherapeutics, Inc.

05.21.03
Valentis Licenses Delivery Technology to Juvaris BioTherapeutics

04.15.03
John F. Warner, Ph.D. Appointed Chief Scientific Officer Of Juvaris BioTherapeutics, Inc.

03.05.03
Martin D. Cleary Becomes Chairman, President And Chief Executive Officer of Juvaris BioTherapeutics